Combined targeted therapy against GLI1 and CCL2/CCR2‐TAMs can significantly inhibit EHF‐mediated CCA development, providing a promising treatment strategy for CCA patients with EHF upregulation. The gene discussed is CCL2; the disease is cholangiocarcinoma.